M&A Deal Summary

Horizon Therapeutics Acquires Boehringer Ingelheim - Interferon Gamma-1b

On May 19, 2016, Horizon Therapeutics acquired life science company Boehringer Ingelheim - Interferon Gamma-1b from Boehringer Ingelheim for 25M EUR

Acquisition Highlights
  • This is Horizon Therapeutics’ 6th transaction in the Life Science sector.
  • This is Horizon Therapeutics’ 9th largest (disclosed) transaction.
  • This is Horizon Therapeutics’ 1st transaction in Germany.

M&A Deal Summary
Date 2016-05-19
Target Boehringer Ingelheim - Interferon Gamma-1b
Sector Life Science
Buyer(s) Horizon Therapeutics
Sellers(s) Boehringer Ingelheim
Deal Type Divestiture
Deal Value 25M EUR

Target

Boehringer Ingelheim - Interferon Gamma-1b

Germany
Boehringer Ingelheim - Interferon Gamma-1b comprises rights to manufacture the pharmaceutical Interferon Gamma-1b, which Boehringer Ingelheim commercializes under the trade names IMUKIN, IMUKINE, IMMUKIN and IMMUKINE in an estimated 30 countries primarily in Europe and the Middle East.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Horizon Therapeutics

Dublin, Ireland
Category Company
Founded 2005
Sector Life Science
Employees2,100
Revenue 3.2B USD (2021)
DESCRIPTION

Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Therapeutics was founded in 2005 and is based in Dublin, Ireland.

DEAL STATS #
Overall 6 of 11
Sector (Life Science) 6 of 11
Type (Divestiture) 3 of 4
Country (Germany) 1 of 1
Year (2016) 1 of 2
Size (of disclosed) 9 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-11 Crealta Pharmaceuticals

Glendale, Wisconsin, United States

Crealta is a specialty pharmaceutical company focused on innovative therapeutics designed to improve patient outcomes. The company, which has two marketed medicines KRYSTEXXA and MIGERGOT, was formed to acquire, develop and market specialty medicines with a focus on select physician specialties.

Buy $510M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-09-12 Raptor Pharmaceuticals

Novato, California, United States

Raptor Pharmaceutical Corp. is a bio pharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases. Raptor Pharmaceuticals Corp. was established in 2005 and is headquartered in Novato, California.

Buy $800M

Seller(S) 1

SELLER

Boehringer Ingelheim

Ingelheim am Rhein, Germany
Category Company
Sector Healthcare Services
DESCRIPTION

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 3
Country (Germany) 1 of 2
Year (2016) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-06-17 Actimis Pharmaceuticals

San Diego, California, United States

Actimis is a biopharmaceutical company focused exclusively on the research and development of small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis.

Buy $515M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-13 ViraTherapeutics

Innsbruck, Austria

ViraTherapeutics GmbH is a biopharmaceutical company developing promising innovative virus-based immunotherapeutics for the treatment of cancer. ViraTherapeutics developes the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)), which is being investigated alone and in combination with other therapies. ViraTherapeutics GmbH was founded in 2013 and is based in Innsbruck, Austria.

Buy €210M
Mergr

Product

Company

Legal